Literature DB >> 8973736

Paraneoplastic pemphigus.

G J Anhalt1.   

Abstract

Paraneoplastic pemphigus has been established as a newly recognized but distinctive syndrome. The syndrome has distinctive clinical, histologic, and immunopathologic features that are consistent between affected individuals. It is intriguing that the autoimmune disease is associated with a very small number of unusual lymphoreticular malignancies. Its very restricted association is encouraging in that it implies there may be a common and identifiable mechanism by which these tumors induce the autoimmunity. Future important goals include the following. First, the genes that encode the as yet uncharacterized protein antigens must be identified and their exact nature determined. It is possible that one of these antigens may represent a biologically important epithelial adhesion molecule. Second, the mechanism or mechanisms by which the tumor cells drive the autoimmune disease must be determined. This may have broader implications for other paraneoplastic diseases such as tumor-associated autoimmune cytopenias or myasthenia. Finally, defining the basic mechanisms of disease induction may lead to improved treatment for the disease. At present it remains a devestating disease with a frighteningly high mortality. Fortunately, recent early diagnosis and intervention with combined prednisone-cyclosporine therapy have provided at least some hope of controlling the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8973736

Source DB:  PubMed          Journal:  Adv Dermatol        ISSN: 0882-0880


  20 in total

Review 1.  Intravenous immunoglobulin for treatment of pemphigus.

Authors:  Lehavit Akerman; Daniel Mimouni; Michael David
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 2.  What's new in blistering disorders?

Authors:  Paru Chaudhari; M Peter Marinkovich
Journal:  Curr Allergy Asthma Rep       Date:  2007-07       Impact factor: 4.806

Review 3.  Pemphigus.

Authors:  Michael Kasperkiewicz; Christoph T Ellebrecht; Hayato Takahashi; Jun Yamagami; Detlef Zillikens; Aimee S Payne; Masayuki Amagai
Journal:  Nat Rev Dis Primers       Date:  2017-05-11       Impact factor: 52.329

Review 4.  Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management.

Authors:  Minhee Kim; Luca Borradori; Dédée F Murrell
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

5.  Improved outcomes after complete resection of underlying tumors for patients with paraneoplastic pemphigus: a single-center experience of 22 cases.

Authors:  Jun Zhang; Qi-lu Qiao; Xi-xue Chen; Ping Liu; Jian-xing Qiu; Hu Zhao; Jian-xun Zhao; Yu-cun Liu; Yuan-lian Wan
Journal:  J Cancer Res Clin Oncol       Date:  2011-02       Impact factor: 4.553

6.  Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice.

Authors:  Hayato Takahashi; Michiyoshi Kouno; Keisuke Nagao; Naoko Wada; Tsuyoshi Hata; Shuhei Nishimoto; Yoichiro Iwakura; Akihiko Yoshimura; Taketo Yamada; Masataka Kuwana; Hideki Fujii; Shigeo Koyasu; Masayuki Amagai
Journal:  J Clin Invest       Date:  2011-08-08       Impact factor: 14.808

7.  Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice.

Authors:  M Amagai; T Nishikawa; H C Nousari; G J Anhalt; T Hashimoto
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

Review 8.  Autoimmune bullous dermatoses in the elderly: diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human.

Authors:  Isabelle Schepens; Fabienne Jaunin; Nadja Begre; Ursula Läderach; Katrin Marcus; Takashi Hashimoto; Bertrand Favre; Luca Borradori
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

10.  Periplakin gene targeting reveals a constituent of the cornified cell envelope dispensable for normal mouse development.

Authors:  Sirpa Aho; Kehua Li; Young Ryoo; Clair McGee; Akemi Ishida-Yamamoto; Jouni Uitto; John F Klement
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.